Novartis Typhoid Vaccine Deal With India’s BioE Shows New Licensing Model
This article was originally published in The Pink Sheet Daily
Executive Summary
Biological E Limited will develop Novartis’ Vi-CRM197 beyond Phase II; the firm will gain rights to a second vaccine against typhoid and paratyphoid upon completion of proof of concept studies.
You may also be interested in...
Novartis Typhoid Vaccine Seeks Partner After Securing Clinical Trial Site
Phase II study is ongoing in Pakistan, a year after Novartis convinced the Pakistani government to lift its ban on clinical trials. Antimalarials with a different mechanism of action than Coartem are in Phase I and II trials.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.